1. Home
  2. TWST vs NRIX Comparison

TWST vs NRIX Comparison

Compare TWST & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$46.04

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.79

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWST
NRIX
Founded
2013
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
TWST
NRIX
Price
$46.04
$16.79
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$47.89
$29.46
AVG Volume (30 Days)
1.4M
1.3M
Earning Date
02-02-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$391,557,000.00
$83,980,000.00
Revenue This Year
$16.77
N/A
Revenue Next Year
$15.06
$20.16
P/E Ratio
N/A
N/A
Revenue Growth
18.59
53.95
52 Week Low
$23.30
$8.18
52 Week High
$54.74
$22.50

Technical Indicators

Market Signals
Indicator
TWST
NRIX
Relative Strength Index (RSI) 69.16 41.48
Support Level $39.66 $16.15
Resistance Level $43.34 $19.65
Average True Range (ATR) 2.50 1.11
MACD 0.16 -0.31
Stochastic Oscillator 77.41 17.12

Price Performance

Historical Comparison
TWST
NRIX

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: